TECENTRIQ® (atezolizumab) and new safety concern of immune-related nephritis

Roche Singapore Pte Ltd would like to inform healthcare professionals of the new safety concern of immune-related nephritis associated with Tecentriq^® (atezolizumab). Immune-related nephritis is a rare complication of checkpoint inhibitors therapy, with the most commonly reported underlying pathology being acute tubulo-interstitial nephritis. The most common presentation of immune-related nephritis includes asymptomatic increase in creatinine levels. In the absence of alternative etiologies (e.g. prerenal and postrenal causes, concomitant medications), immune-related nephritis is defined as a renal dysfunction requiring steroids treatment and/or confirmed by biopsy. Healthcare professionals are advised to monitor patients for changes in renal function and to withhold Tecentriq^® for moderate (Grade 2) immune-related nephritis, and permanently discontinue Tecentriq^® for severe nephritis (Grade 3 and 4). It is also recommended to administer corticosteroids and/or additional immunosuppressive agents as clinically indicated. Roche Singapore Pte Ltd is working with HSA to update the Singapore package insert for Tecentriq^® to include the risk of immune-related nephritis. Please refer to the letter for details.

Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of these letters can be found in the MOH Alert System, which is accessible via the Health Professionals Portal (HPP), a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://hpp.moh.gov.sg ↗ (opens in new tab) and follow the procedures below to access the MOH Alert system.

Step 1: Select your profession under ‘For Healthcare Professionals’.

Step 2: Click on ‘Useful links’.

Step 3: Click on ‘MOH Alert’ and log in via Singpass.

Step 4: Click on ‘Drug Alerts’ or ‘Med Device Alerts’ to view the DHCPLs.